Janssen Presents First Results from Dual Bispecific

BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from...

Related Keywords

United States ,Chicago ,Illinois ,Israel ,Beerse ,Region Flamande ,Belgium ,American ,Edmond Chan ,Yael Cohen ,Arnob Banerjee ,Companies Of Johnson ,Committee For Medicinal Products Human Use ,Janssen Research Development ,Hematology Institute Tel ,Early Development Oncology ,Aviv Sourasky Medical Center ,American Society Of Clinical Oncology ,Janssen Pharmaceutical Companies Of Johnson ,European Medicines Agency ,American Cancer Society ,Johnson ,None Of The Janssen Pharmaceutical Companies ,Exchange Commission ,European Commission ,Janssen Pharmaceutical Companies ,Clinical Oncology ,Annual Meeting ,Myeloma Unit ,Confidence Interval ,Not Estimable ,Senior Director ,Area Lead Haematology ,Global Medical Head ,Janssen Research ,Medicinal Products ,Human Use ,Breakthrough Therapy Designation ,Orphan Drug Designation ,Multiple Myeloma ,Pharmaceutical Companies ,Infectious Diseases ,Janssen Cilag Limited ,Private Securities Litigation Reform Act ,Janssen Pharmaceutica ,Janssen Pharmaceutical ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Results From ,With Teclistamab ,Simultaneously Targeting ,Refractory Multiple Myeloma ,Participants With Relapsed ,Refractory Multiple ,Participants With Multiple Myeloma ,Subcutaneous Daratumumab Regimens ,Bispecifict Cell Redirection Antibodies ,Daratumumab Subcutaneously ,Versus Daratumumab ,Bispecific Antibody ,Teclistamab Each ,Combination With ,Programmed Cell Death ,Study Comparing Talquetamab ,Combination With Daratumumab ,Pomalidomide Versus Daratumumab ,Combination With Pomalidomide ,Today Population Factsheets ,Janssen Emea ,